Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen

DRUG5 trials

Sponsors

Novo Nordisk A/S, Trinity College Dublin, Clinical Pharmacology, Department of, Karolinska University Hospital

Conditions

AdipositasAtrial fibrillationCardiovascular disorders: Hypertension and ObesityObesityObesity and overweight

Phase 3

Long-term safety and efficacy of semaglutide s.c. once-weekly on weight management in children and adolescents (aged 6 to <18 years) with obesity or overweight

Active, not recruitingCTIS2022-502922-41-00

Novo Nordisk A/SObesity and overweight

Start: 2023-07-03Target: 86Updated: 2025-11-03

Semaglutide for people with obesity and resistant hypertension (SUPPORT): a pilot, randomized, parallel-group, integrated, multicentre clinical trial.

RecruitingCTIS2024-513958-29-00

Trinity College DublinCardiovascular disorders: Hypertension and Obesity

Start: 2025-04-24Target: 50Updated: 2025-11-10

Phase 4

Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c. 2.4 mg Once-weekly

Active, not recruitingCTIS2023-508055-40-00

Novo Nordisk A/SObesity

Start: 2025-02-18Target: 309Updated: 2025-12-14

The GOAL study: GLP-1 receptor agonist treatment for Adolescents with Obesity secondary to Antipsychotic Medication - A feasibility study

RecruitingCTIS2024-517471-21-02

Clinical Pharmacology, Department ofAdipositas

Start: 2025-06-24Target: 34Updated: 2025-05-02

Waiting on Atrial fibrillation Intervention Therapy (WAIT) Study

Not yet recruitingCTIS2025-524182-25-00

Karolinska University HospitalAtrial fibrillation

Target: 200Updated: 2025-12-17